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Common variable immunodeficiency (CVID) is one of the most common and clinically impor-
tant primary immune deficiencies. CVID patients have poor humoral immunity, resulting in
recurrent infections of the gastrointestinal and upper respiratory tracts, as well as increased
incidence of some forms of cancers and autoimmune diseases. The treatment for CVID
is IgG replacement, often given as intravenous immunoglobulins (IVIg). IVIg consists of
monomeric IgG purified from pooled plasma from healthy donors and is used to treat an
increasing number of conditions including autoimmune diseases. In the case of CVID, IVIg
has mainly been seen as reconstitution therapy, providing patients with pathogen-specific
antibodies. Recent evidence shows that IVIg has diverse effects on the immune system
of CVID patients, and one important component is that IVIg alleviates the state of chronic
immune activation. In this review, we will discuss causes and consequences of persis-
tent immune activation in CVID, possible underlying mechanisms for how IVIg treatment
reduces immune activation, and implications for our understanding of primary as well as
acquired immune deficiencies.
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INTRODUCTION
Diagnosis of common variable immunodeficiency (CVID) is
based on low levels of IgG and IgA and lack of specific IgG response
following vaccination (1). Several genetic mutations associated
with CVID have been identified but for a significant proportion of
patients the exact cause is unknown (2). CVID patients, thus, are
a heterogeneous group characterized by poor humoral immunity,
resulting in recurrent infection of the gastrointestinal and upper
respiratory tracts. CVID is also associated with non-infection
related complications including cancers, mainly non-Hodgkin’s
lymphoma, and autoimmune diseases such as idiopathic throm-
bocytopenia purpura and autoimmune hemolytic anemia, con-
tributing to a significantly shorter life expectancy (3, 4). It has
become clear that defects in the immune system in CVID go
beyond humoral immunity with significant changes and persistent
activation of the cellular immune system, involving dendritic cells
(DCs), CD8 T cells, CD4 T cells, invariant natural killer T (iNKT)
cells, and regulatory T cells (Tregs). The treatment for CVID is IgG
replacement, often given as intravenous immunoglobulins (IVIg).
IVIg consists of monomeric IgG purified from pooled plasma from
healthy donors and it is used to treat an increasing number of con-
ditions (5), including autoimmune diseases. The mechanisms of
action of IVIg in treatment of autoimmune diseases are numerous
and controversial (6, 7). In the case of CVID, it has mainly been
seen as a reconstitution therapy, providing patients with pathogen-
specific antibodies, but evidence now shows that IVIg has a variety
of effects on the immune system of CVID patients (8) and can
alleviate the state of chronic immune activation. In this review,
we will discuss the causes and consequences of innate and adap-
tive immune activation, and how IVIg treatment reduces immune
activation in CVID focusing on data obtained ex vivo. We will also
discuss the similarities between primary and secondary immune
deficiencies and the possible implications for our understanding
of those diseases.
INNATE IMMUNE ACTIVATION
Common variable immunodeficiency patients present defects in
several arms of the innate immune system. Natural killer (NK)
cells express a wide repertoire of activating and inhibitory recep-
tors and are part of the innate defenses against viral infections
and tumors (9). NK cells were first recognized for their cytotoxic
capacity but they can also produce cytokines and have regulatory
properties (10). The frequency of NK cells has been reported to
be lower in CVID (11). Detailed studies of NK cells in CVID are
lacking, and the effects IVIg treatment may have on NK cell fre-
quency, phenotype, and functions are unknown. Because of their
antitumor function, decline of NK cells could contribute to the
increased risk of cancer in CVID patients.
Polymorphonuclear neutrophils (PMNs) are an important
component of the innate immune system. In response to
pathogens, PMN can rapidly migrate to the site of inflamma-
tion and have microbicidal activity by the release of proteolytic
enzymes and antimicrobial peptides as well as production of
reactive oxygen species (ROS) (12). In CVID, PMNs have been
reported to express lower levels of CD11b, CD16b, and CD15,
suggesting a maturation defect (13). The same study also reported
impaired phagocytosis of E. coli and reduced ROS production after
TLR stimulation by PMN from CVID patients. The patients in
this study were all under IVIg treatment, and the effects of IVIg on
PMN phenotype and function therefore remain undetermined.
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However, in vitro experiments performed on whole blood from
healthy individuals suggest that low doses of IVIg, as used for
treatment of CVID, can induce CD11b expression and increase
the ROS response (14).
Monocytes are myeloid-derived cells with phagocytosis and
antigen presentation capacities. They can rapidly differentiate
into tissue-resident macrophages and DCs after leaving the blood
stream. Monocytes play an important role in various inflamma-
tory conditions (15). In CVID, the frequency of pro-inflammatory
CD14bright CD16+ monocytes is elevated and these cells express
higher levels of HLA-DR indicating a higher activation level (16).
Another study showed that IVIg temporarily reduced the fre-
quency of pro-inflammatory monocytes 4 h after injection and
that the levels returned to baseline after 20 h (17). Furthermore,
IVIg may reduce TNF production by monocytes from CVID
patients, possibly by triggering of the inhibitory receptor FcγRIIb
(17). Monocytes from CVID patients were also found to have
increased production of ROS, and this was inversely correlated
with CD4 counts (18).
Dendritic cells are professional antigen presenting cells (APCs)
specialized in capturing, processing, and presenting antigens to
initiate immune responses to pathogens. After TLR activation,
DCs will mature and increase the expression of co-stimulatory
molecules to provide the second signal needed to activate T cells.
Bayry et al. showed that in vitro differentiation of monocytes from
CVID patients into DCs (19) is defective, and that normal differ-
entiation could be restored by natural antibodies against CD40
present in IVIg (20). However, the in vivo relevance of this mecha-
nism remains to be investigated as ex vivo DCs from CVID patients
present a different phenotype. CVID patients have reduced fre-
quencies of plasmacytoid and myeloid DCs (21), and the residual
myeloid DCs have increased expression of co-stimulatory mol-
ecules CD80 and CD83 (22). The frequency of myeloid DCs is
partially restored following initiation of IVIg treatment and the
expression of CD80 is significantly decreased. Moreover, myeloid
DCs in treatment-naïve CVID patients display an abnormal profile
of group I CD1 molecules characterized by an elevated representa-
tion of the CD1c+ subset. In addition, the CD1c+ and the CD1c−
subsets of DCs have higher CD1a and CD1b expression in these
patients (23), whereas CD1d is expressed at similar levels between
CVID patients and controls, being present on the majority of the
cells. Following the increase in IgG level after initiation of replace-
ment therapy, the CD1c subset frequency is normalized together
with the expression levels of CD1a and CD1b, while CD1d expres-
sion is unaffected. These findings suggest that IgG can regulate
the expression of group I CD1 molecules in vivo. Earlier stud-
ies in vitro indicated that this effect is mediated by binding to
the FcγRIIb (24). It remains to be investigated if the increased
expression of CD1a in treatment-naïve CVID patients can lead to
aberrant activation of the CD1a restricted T cells that are present
in the normal repertoire (25).
Because they can rapidly be activated and produce cytokines
without previous encounter of their antigen, iNKT cells are some-
times considered to be part of the innate immune system (26).
They recognize endogenous and bacterial-derived glycolipids pre-
sented by CD1d molecules. It is believed that iNKT cells are
important for the control of both bacterial and viral infections
and they are also believed to be involved in immune surveillance
against cancer and to have the capacity to regulate auto-immunity
(26). iNKT cells are numerically reduced in CVID (27) and present
elevated expression of HLA-DR, CD161, and PD-1 (22), signs of
activation and exhaustion. In addition, the distribution of iNKT
cell subsets defined by CD4 and CD8 is skewed in CVID, with an
increase in the CD4+ and a decrease in the CD8+ subset reported
in one cohort (28). The function of iNKT seems to be relatively
preserved in treatment-naïve CVID patients, as only a trend for
reduced IFNγ production was seen after stimulation with the
model antigen α-Gal–Cer (29). Increased IFNγ production by
iNKT cells was reported for a small number of CVID patients
on going IVIg after in vitro expansion (30). The frequency of
iNKT cells does not improve by reconstitution therapy, and HLA-
DR remains elevated. However, expression of CD161 and PD-1 is
reduced when CVID patients are under IVIg treatment (22), indi-
cating that IVIg can alleviate iNKT cell activation and exhaustion
in patients. Because of the important role of iNKT cells in tumor
surveillance and immune regulation, it is possible that the loss
of these cells is contributing to the increased risks of cancer and
auto-immunity in CVID patients.
ADAPTIVE IMMUNE ACTIVATION
Treatment-naïve CVID patients present low-CD4 T cell counts,
in some cases down to numbers that would be considered AIDS-
defining in HIV-1 infected patients. Following IVIg initiation, CD4
counts increase in the majority of CVID patients and can reach
normal levels in some cases (22, 31). It is noteworthy that a similar
effect has been reported in HIV-1 patients treated with IVIg (32,
33). The mechanisms by which IVIg can normalize CD4 counts
remain elusive, but Dolcino et al. reported that lower expression
of LEPR, a gene important for CD4 proliferation, was normalized
after IVIg treatment in CVID patients (31). CD8 T cell counts in
CVID patients are in general not different from healthy controls
but some patients have an expansion of this population. There-
fore, the inverted CD4:CD8 ratio seen in CVID is mostly due to
their low-CD4 count. CD4 T cells in CVID have elevated levels
of the activation markers Ki67, CD38, and HLA-DR, as well as
exhaustion markers PD-1 and CTLA-4. The expression levels of
activation and exhaustion markers remained elevated for up to
1 year on IVIg treatment (22). Interestingly, another study found
that IVIg treatment could reduce PD-1 expression on CD4 T cells
and restore their response to bacteria (34).
Similar to the CD4 T cell compartment, CD8 T cells in
treatment-naïve CVID have elevated expression of activation
markers Ki67 and co-expression of CD38 and HLA-DR. IgG
replacement therapy leads to reduced expression of Ki67, CD38,
and HLA-DR on CD8 T cells (22), indicating that IgG replacement
may help control infections or infection-associated factors that are
implicated in chronic activation of the CD8 T cells. Expression of
some activation markers on CD8 T cells and exhaustion markers
on CD4 T cells correlate positively with age in IVIg-naïve CVID
patients (22), suggesting that immune activation and exhaustion
are developing progressively over time. Furthermore, the ratio
of activated T cells to Tregs was found to be higher in CVID
patients with auto-immunity compared to patients without auto-
immunity (35). Therefore, early initiation of IgG replacement
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therapy in CVID patients may be beneficial by preventing fur-
ther increase in T cell activation. However, diagnosis of CVID is
frequently delayed by 6–8 years after the onset of symptoms (1).
Regulatory T cells are key regulators of immune responses
and they play a crucial role in limiting unwanted and persis-
tent immune activation. Several studies demonstrated that Tregs
are reduced in CVID patients (22, 36–38) and that residual Tregs
appear to have reduced suppressive capacity (39). An increase in
Tregs was reported 30 min after IVIg infusion in CVID patients
(38). This increase seems to be only transient as no sustained
effect on Treg frequency was observed between samples obtained
at baseline and up to 1 year after initiation of IVIg treatment (22).
The inability of IVIg to restore normal frequency and function of
Tregs may contribute to the increased risk of auto-immunity in
CVID patients (36).
WHAT IS DRIVING IMMUNE ACTIVATION IN CVID?
Signs of activation in both monocytes and DCs are associated with
T cell activation (16, 22, 40), suggesting that persistent innate acti-
vation contribute to chronic activation of the adaptive immune
system. We propose a model where recurrent and chronic infec-
tions at mucosal surfaces in treatment-naïve CVID patients result
in sustained activation of monocytes and DCs, and that these cells
in turn promote T cell activation (Figure 1). In this model, one
possible mechanism by which IVIg reduces activation of T cells is
by acting at the level of the APCs. In vivo and in vitro studies sup-
port the notion that IVIg reduces T cells activation indirectly by
acting on APCs rather than on the T cells themselves (41–45).
IVIg may act directly on APCs via Fc-receptors, or have indi-
rect effects on APCs activation by reducing the infection burden.
However, persistent activation of monocytes and DCs is seen in
CVID patients even after IVIg therapy and the causes are largely
unknown.
CMV infection has been associated with complications in CVID
patients (46, 47) and thus CMV is a possible candidate as a cause
for chronic immune activation in CVID. Resurgence of endoge-
nous retroviruses (ERVs) in the absence of LPS-specific antibodies
has been reported in a mouse model (48). IVIg preparations con-
tain antibodies specific for both CMV (49) and LPS (50), and
may therefore help reduce the pressure on the immune system by
supporting immune control of CMV and by preventing activa-
tion of ERVs. Enteric virus infections were found in 25% of CVID
and CVID-like patients compared to 9% in controls, and these
infections were associated with increased levels of calprotectin,
a marker of inflammation, and low levels of IgA (51). Therefore,
enteric viruses may also contribute to increased immune activation
in CVID patients. However, only few CVID patients present the
CD8 T cell expansion typically associated with chronic viral infec-
tions, suggesting that other causes may be involved. Soluble CD14
(sCD14), a marker associated with monocyte activation and pos-
sibly microbial translocation, is elevated in CVID (16, 22, 52). LPS
levels were found to be elevated in one cohort of treatment-naïve
CVID patients and were reduced following replacement therapy
(34). However, we and others were unable to detect elevated LPS
levels in the circulation of CVID patients [our unpublished data
and Ref. (16, 52)]. Therefore, more investigations are needed to
clarify the role of microbial translocation in CVID patients. The
loss of Tregs as well as iNKT cells with regulatory capacities may
contribute to the persistent immune action seen in CVID. These
two populations appear to not recover after initiation of IVIg
FIGURE 1 | Pathological changes and activation of cellular immunity in
CVID is partially alleviated after immunoglobulin replacement therapy.
IgG replacement therapy restores humoral immunity and provides better
control of microbes and pathogens, reducing the infection burden on the
immune system. This together with triggering of the FcR-mediated inhibitory
effects on antigen presenting cells leads to reduced activation of CD8 T cells,
iNKT cells, and DCs (A) and improvement in CD4 T cell counts and DC
count (B).
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therapy (22), possibly providing an explanation as to why immune
activation remains elevated.
SIMILARITIES BETWEEN PRIMARY AND SECONDARY
IMMUNE DEFICIENCIES
Some of the immunological perturbations observed in treatment-
naïve CVID patients are strikingly similar to those seen in
untreated HIV-1 infection. HIV-1 infection leads to chronic
immune activation characterized by increased T cell activation
and exhaustion, elevated levels of sCD14 and a partial loss of CD4
T cells, DCs, iNKT cells, and Tregs. These features are also found
in CVID patients. T cell activation is closely associated with HIV-1
disease progression (53) but it is unknown if similar associations
exists in CVID. IL-6 is a predictor of all-cause mortality (54) and
disease progression (55) in HIV-1 infection, and has been asso-
ciated with opportunistic infections (56) and increased risk of
cancer (57). Interestingly, several studies reported an increase in
IL-6 in CVID (58); however, it has not been studied as a bio-
marker of disease progression or complications. CVID and HIV-1
also present a similar signature in gene expression in the intesti-
nal epithelium with up-regulation of innate immune gene and
down-regulation of lipid and carbohydrate metabolism genes and
transport of micronutrients genes (59), suggesting that events at
the mucosal barrier may be involved in the similarities between the
two diseases. Moreover, sCD14 levels have been found to associate
with immune activation in both CVID (52) and HIV-1 (60), sug-
gesting that monocyte activation is common to both conditions.
IL-2 administration in combination with antiretroviral treatment
results in increased CD4 counts (61), and expansion of iNKT cells
(62) and NK cells (63) in HIV-1 infected patients. IL-2 has also
been studied as a complementary therapy in CVID, resulting in
increased T cell responses to mitogens and soluble antigens in the
absence of changes in CD4 count and NK cell frequency (64) while
iNKT cell frequency was not evaluated. Because of the similarities
between CVID and HIV-1 disease, it is not unexpected that IVIg
treatment can have modest effects on T cell activation and CD4
count in HIV-1 infection (32, 33). Therefore, it is possible that
IVIg could be beneficial as a complement therapy for patients that
have residual immune activation despite successful viral control
on ART.
CONCLUDING REMARKS
Intravenous immunoglobulin provides CVID patients with a par-
tial replacement for their defective humoral immunity. However,
CVID patients also present abnormalities in cellular immunity
in a way similar to what is often seen in other conditions asso-
ciated with chronic immune activation such as HIV-1 infection.
Some of these changes are normalized by IVIg treatment, suggest-
ing that IVIg may also be beneficial in other immune deficiencies
characterized by persistent immune activation. IVIg seems to have
short-lived effects on the monocyte and Treg populations, whereas
the reduction of activation in DCs, iNKT cells, and T cells appear to
be sustained. However, the vast majority of immunological stud-
ies of CVID have been performed on patients who are already
on IVIg replacement, therefore, missing or underestimating some
of the abnormalities in CVID that are corrected by IVIg. More
studies of treatment-naïve CVID patients are needed to better
understand what is driving immune activation in CVID and how
IVIg is helping to improve cellular immunity. Furthermore, it will
be important to investigate how we can restore the compartments
that are not recovering after initiation of IVIg, such as Tregs and
iNKT cells. Persistent loss of these cells may help explain why some
CVID patients still suffer from severe inflammatory complications,
such as interstitial lung disease and autoimmune enteropathy, even
when on replacement therapy. Cellular therapy has been safely and
successfully used to treat two CVID patients suffering from CMV
intestinal disease by injection of autologous specific cytotoxic T
cell lines expanded ex vivo (65). Thus, cellular therapy may rep-
resent a good complement to IVIg treatment to help restore a
functional immune system in CVID patients.
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